Psoriatic arthritis (PsA) is an inflammatory joint disease that is highly comorbid with psoriasis, and characterized by pain, stiffness, and/or swelling in the joints, ligaments, and tendons. In March of 2014, apremilast (Otezla) became the first oral therapy approved and launched for the treatment of active PsA in the United States. This report tracks the postlaunch awareness, trial, and usage of Otezla among surveyed rheumatologists for the treatment of PsA. The third wave of the syndicated report assesses physician perceptions at one year after the launch of Apremilast.

Questions Answered in This Report:

  • The PsA market has numerous effective subcutaneous or intravenous options for patients; however, opportunity exists for patient populations averse to self- or hospital-administered injection. Where will Otezla, an oral option, be placed in the treatment algorithm to best meet the needs of the current patient population?

  • In the treatment of PsA, new and emerging therapies have generally been reserved for refractory patients–those who have failed at least one standard TNF-inhibitor–but some interviewed physicians express increasing comfort prescribing Otezla earlier in the treatment algorithm. Which patient types do surveyed physicians find Otezla best-suited for?

  • Physicians’ current armamentarium for the treatment of PsA includes many well-established therapies; however, suboptimal side-effect profiles, administration, and cost make some therapies unsuitable for many patients. How will the launch of Otezla affect other established brands in the marketplace?


Markets covered: United States.

Primary research: 102 country-specific interviews with rheumatologists. In addition, 10 surveyed rheumatologists participated in a qualitative interview.

Population segments in market research: Treatment-naive, treatment additions, treatment switches, combination therapy, treatment nonresponders, mild PsA, moderate PsA, severe PsA, enthesitis, dactylitis, axial PsA, peripheral PsA.

Emerging therapies: 4 Phase III drugs are covered in this report.

Author(s): Melissa Curran (Research Associate)